Specializes in dermatology, leveraging microbiome-based therapies to treat skin diseases and conditions.
Azitra, Inc., headquartered in Branford, Connecticut, is a pioneering early-stage biopharmaceutical company dedicated to developing innovative therapies in precision dermatology. Leveraging its expertise in engineered proteins and live biotherapeutic products, Azitra focuses on addressing a spectrum of challenging skin diseases with high unmet medical needs.
One of Azitra's primary developments is ATR-12, a genetically modified strain of S. epidermidis currently in Phase Ib clinical trials. ATR-12 is specifically designed to target Netherton syndrome, a rare genetic skin disorder characterized by chronic skin inflammation and a defective skin barrier function. By harnessing the therapeutic potential of engineered microbes, Azitra aims to provide a novel treatment option for patients grappling with this debilitating condition.
In addition to ATR-12, Azitra is advancing other promising candidates in its pipeline. ATR-04, another genetically modified strain of S. epidermidis, is being developed to mitigate the papulopustular rash commonly experienced by cancer patients undergoing treatment with epidermal growth factor receptor inhibitors (EGFRIs). This condition, known for its impact on quality of life, poses a significant challenge in cancer therapy, highlighting the critical need for effective interventions.
Furthermore, Azitra is pursuing ATR-01, an engineered recombinant human filaggrin protein intended for the treatment of ichthyosis vulgaris, a genetic disorder characterized by dry, scaly skin. By targeting the underlying molecular mechanisms of skin diseases, Azitra aims to deliver therapeutic innovations that not only alleviate symptoms but also improve long-term patient outcomes.
Azitra has strategically collaborated with industry leaders such as Bayer to accelerate its research and development efforts. These partnerships bolster Azitra's capabilities in advancing its pipeline and bringing innovative dermatological treatments to market. Founded in 2014, Azitra continues to drive forward with its mission to transform the landscape of dermatology through cutting-edge biotechnologies and a steadfast commitment to addressing unmet medical needs.